The Changing Clinical Landscape in 2026: Understanding Challenges, Shaping Solutions

Evening Two – The GLP-1 (Ozempic) Era: Nutritional Safeguards and Mineral Balance

With GLP-1 agonists reshaping weight management and metabolic care, nutritional risk is easy to overlook. We will examine how GLP-1 therapies alter appetite, intake, gastric emptying and nutrient absorption, and why this can impact protein status, micronutrients and key minerals. The session will outline pragmatic safeguards: baseline assessment, monitoring, and targeted nutritional and mineral support to help reduce adverse effects and protect long-term health while patients are on (or coming off) GLP-1 agents.